PRKDC and cancer: Raloxifene, erlotinib, and gefitinib, which have been shown to inhibit AOX163, as well as artemether, which we identified as an MMEJ outcome inhibitor, exert synthetic lethality in PRKDC-deficient iPSCs and in BRCA2-deficient Capan-1 cells (Fig. 5d–f), making them interesting drug candidates for the treatment of NHEJ- as well as HR-deficient cancers.